News
CELG-RT
0.0590
0.00%
0.00
Weekly Report: what happened at CELG RT last week (0408-0412)?
Weekly Report · 3d ago
Weekly Report: what happened at CELG RT last week (0401-0405)?
Weekly Report · 04/08 09:15
Weekly Report: what happened at CELG RT last week (0325-0329)?
Weekly Report · 04/01 09:15
Weekly Report: what happened at CELG RT last week (0318-0322)?
Weekly Report · 03/25 09:15
Weekly Report: what happened at CELG RT last week (0311-0315)?
Weekly Report · 03/18 09:15
Weekly Report: what happened at CELG RT last week (0304-0308)?
Weekly Report · 03/11 09:14
Weekly Report: what happened at CELG RT last week (0226-0301)?
Weekly Report · 03/04 09:15
Weekly Report: what happened at CELG RT last week (0219-0223)?
Weekly Report · 02/26 09:16
Weekly Report: what happened at CELG RT last week (0212-0216)?
Weekly Report · 02/19 09:17
Weekly Report: what happened at CELG RT last week (0205-0209)?
Weekly Report · 02/12 09:15
Weekly Report: what happened at CELG RT last week (0129-0202)?
Weekly Report · 02/05 09:16
Weekly Report: what happened at CELG RT last week (0122-0126)?
Weekly Report · 01/29 09:15
Weekly Report: what happened at CELG RT last week (0115-0119)?
Weekly Report · 01/22 09:16
Weekly Report: what happened at CELG RT last week (0108-0112)?
Weekly Report · 01/15 09:16
Weekly Report: what happened at CELG RT last week (0101-0105)?
Weekly Report · 01/08 09:16
Weekly Report: what happened at CELG RT last week (1225-1229)?
Weekly Report · 01/01 09:15
Weekly Report: what happened at CELG RT last week (1218-1222)?
Weekly Report · 12/25/2023 09:16
Weekly Report: what happened at CELG RT last week (1211-1215)?
Weekly Report · 12/18/2023 09:17
Weekly Report: what happened at CELG RT last week (1204-1208)?
Weekly Report · 12/11/2023 09:17
Weekly Report: what happened at CELG RT last week (1127-1201)?
Weekly Report · 12/04/2023 09:16
More
Webull provides a variety of real-time CELG-RT stock news. You can receive the latest news about Bristol-Myers Squibb Company Celegne Contingent Value Rights through multiple platforms. This information may help you make smarter investment decisions.
About CELG-RT
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Its commercial-stage products include REVLIMID (lenalidomide), POMALYST/IMNOVID (pomalidomide), OTEZLA (apremilast), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), VIDAZA, azacitidine for injection (generic version of VIDAZA) and THALOMID (thalidomide). Its clinical trial activity includes trials across the disease areas of hematology, solid tumors, and inflammation and immunology. The Company also markets ISTODAX, which is an epigenetic modifier. The Company is also evaluating AG-221 (enasidenib) in combination with VIDAZA in newly diagnosed acute myeloid leukemia with isocitrate dehydrogenase-2 mutations.